Developer docs
API playgroundTry for free, no card

Search company profiles

Gistem Research S.L.

Full company profile

uuid004htx3

Namestring
Gistem Research S.L.
Legal namestring
GISTEM RESEARCH, S.L.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Gistem Research S.L. is a Spanish biotechnology company founded in 2016 and headquartered in Gijón, Asturias, that develops therapeutic candidates derived from human Uterine Cervical Stem Cells (hUCESC). Its core technology platform centers on the production and application of the cell secretome and exosomes — the bioactive molecules and extracellular vesicles released by these stem cells — rather than the cells themselves. The company advances multiple preclinical programs targeting dry eye disease, inflammatory bowel disease, oral diseases, oncology, and, more recently, cerebral palsy.

Its intellectual property is anchored by patent family PCT/2014/053508, granted in more than 30 jurisdictions including the United States (granted 2025-02-04), Europe (granted 2019-06-17), China, Japan, Mexico, and Australia. Gistem is led scientifically by founders Dr. Francisco Vizoso Piñeiro and Dra. Noemí Eirí­o Díaz, with Dr. Luis Alberto Costa Pérez chairing its Board, and operates with a team of approximately six employees. It maintains a research network with the Jove Hospital Foundation, FICEMU, the University of Santiago de Compostela, the Ministry of Health of Tucumán (Argentina), and the Dale que valen Foundation.

Gistem is pre-clinical and pre-revenue. Its intended business model is to advance its programs through early clinical development and ultimately monetize the platform through out-licensing, co-development partnerships, or future royalty streams; two programs are targeted to enter clinical trials in 2026 and 2027, following positive guidance from the Spanish Medicines Agency on trial design. To date, the only disclosed funding is an IDEPA grant awarded in 2018.

Short descriptiontext

Gistem Research S.L. is a Spanish biotechnology company developing secretome and exosome-based therapies derived from human Uterine Cervical Stem Cells (hUCESC) for ophthalmology, inflammatory bowel disease, oral conditions, oncology, and cerebral palsy applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGijón, Spain
HQ citystring
Gijón
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapies, regenerative medicine, cell secretome research, extracellular vesicles, biotechnology research
Industry3 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Regenerative Medicine Biotechnology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Stem Cell Derivative Products
TypeOne Time License
Description

Development and commercialization of secretome-based therapeutic products for various clinical applications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Revenue expected from future product sales following clinical development.

gistemresearch.com
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary hUCESC technology, cell populations, and production methods to pharmaceutical and biotechnology partners.

gistemresearch.com
3Research Collaborations
TypeProfessional Services
Description

Collaborative research arrangements with academic institutions and healthcare organizations for specific therapeutic applications.

gistemresearch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gistem Research S.L. develops therapeutic products derived from stem cell derivatives, specifically the secretome and extracellular vesicles (exosomes) from human Uterine Cervical Stem Cells (hUCESC). The company produces these biological materials through reproducible, cost-effective methods and targets multiple clinical indications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Two lead programs are expected to enter clinical trials in 2026 and 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Improvement in 90% of uveitis cases with current treatment comparison
+1 more record
Product overview1 text field

Gistem Research S.L. operates as a pioneering biotechnology company focused on developing innovative therapies based on stem cell derivatives. The company's core technology platform centers on hUCESC (human Uterine Cervical Stem Cells) secretome and extracellular vesicles, which are produced in a reproducible and cost-effective manner. The product portfolio includes secretome-based therapeutic products for multiple clinical applications, specifically organized into therapeutic programs targeting Dry Eye Syndrome, Inflammatory Bowel Disease, Oral Diseases, and Oncology. The company's first two programs are expected to enter clinical phase in 2026 and 2027. The therapeutic approach focuses on using stem cell derivatives (secretome and extracellular vesicles) rather than live cells directly, which simplifies regulatory pathways as biological products rather than advanced therapies.

Product and service6 records
1hUCESC Secretome-based Therapy
CategoryBiotechnology / Stem Cell Therapeutics
Description

Secretome-based therapeutic products derived from human Uterine Cervical Stem Cells (hUCESC), containing bioactive molecules offering immunoregulation, healing, and regeneration properties for pharmaceutical partners and healthcare institutions.

2hUCESC Extracellular Vesicles (Exosomes)
CategoryBiotechnology / Stem Cell Therapeutics
Description

Extracellular vesicles derived from human Uterine Cervical Stem Cells (hUCESC), used as therapeutic agents for clinical applications.

3Dry Eye Syndrome Therapeutic Program
CategoryOphthalmology Therapeutic Program
Description

Clinical program targeting dry eye syndrome using secretome-based therapy derived from hUCESC, one of the company's first two lead programs.

4Inflammatory Bowel Disease Therapeutic Program
CategoryGastroenterology Therapeutic Program
Description

Clinical program targeting inflammatory bowel disease using secretome-based therapy derived from hUCESC.

5Oral Diseases Therapeutic Program
CategoryDental / Oral Health Therapeutic Program
Description

Clinical program targeting oral diseases and dental pulp regeneration using secretome-based therapy derived from hUCESC.

6Oncology Therapeutic Program
CategoryOncology Therapeutic Program
Description

Clinical program targeting oncology applications using secretome-based therapy derived from hUCESC, with research showing antitumor effects in breast cancer models.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Dale que valen Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Agreement to establish collaboration framework for research project 'Exploration of the therapeutic effect of intrasanal application of secretome derived from mesenchymal stem cells of the human uterine cervix in cerebral palsy.' Project encompasses complete cycle up to obtaining therapeutic solutions and treatment protocols.

gistemresearch.com
2Ministry of Health of Tucumán
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-22
Description

Framework cooperation agreement between the Ministry of Health of Tucumán (Argentina), GiStem Research S.L., and the Economic Federation for stem cell research. The agreement focuses on secretome-based therapies and includes plans for specific protocols with ethics committee approval for work with selected patients.

gistemresearch.com
3Economic Federation of Tucumán (FET)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-22
Description

Partnered with Ministry of Health of Tucumán and GiStem Research for stem cell research cooperation. FET facilitated Dr. Luis Costa Pérez's involvement and is financing the project.

gistemresearch.com
4Jove Hospital Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research collaboration with the Jove Hospital Foundation in Gijón, where the research unit is located and where initial stem cell research was conducted.

gistemresearch.com
5FICEMU (Foundation for Uterine Stem Cell Research)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foundation supporting research with uterine stem cells. Dr. Francisco Vizoso serves as Director of the Scientific Committee. The foundation has financed multiple research projects.

gistemresearch.com
6University of Santiago de Compostela
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research partner collaborating on various studies including stem cell applications in cancer, ophthalmology, and inflammatory conditions. Located in Galicia, Spain.

gistemresearch.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Capricor Therapeutics
TypeDirect peer
Description

US clinical-stage biotechnology company developing exosome and cell-based therapeutics, notably its lead exosome program CAP-1002 and Deramiocel for Duchenne muscular dystrophy. Directly comparable to Gistem as a stem cell-derived exosome platform targeting inflammatory and regenerative indications.

2Direct Biologics
TypeDirect peer
Description

US-based biotech developing extracellular vesicle (EV) and exosome-based therapies derived from bone marrow mesenchymal stem cells for inflammatory and regenerative indications including wound healing and orthopedic applications. Closely comparable to Gistem's hUCESC-derived exosome platform in technology and target markets.

3Kimera Labs
TypeDirect peer
Description

US biotech focused on mesenchymal stem cell-derived exosome products for regenerative and wellness applications. Direct peer in the MSC-exosome therapeutics space with similar therapeutic claims around immunoregulation and tissue regeneration.

4ExoCoBio
TypeDirect peer
Description

South Korea-based exosome therapeutics developer with MSC-derived exosome products for skin regeneration, atopic dermatitis, and inflammatory conditions. Direct competitor in the cell-derived exosome therapeutics category targeting similar indications.

5Mesoblast
TypeBroad incumbent
Description

Australia-listed clinical-stage biotech developing mesenchymal stem cell-derived therapies (Remestemcel-L, Ryoncil) for inflammatory and immune-mediated diseases including GVHD and heart failure. Larger, more advanced MSC-therapy incumbent with overlapping technology platform and indication strategy.

6Cynata Therapeutics
TypeDirect peer
Description

Australia-based clinical-stage biotech developing iPSC-derived mesenchymal stem cell therapies (CYP-001, CYP-004) for inflammatory conditions including osteoarthritis and GVHD. Directly comparable MSC-derived therapeutic platform targeting similar regenerative and immunoregulatory indications.

7Pluri Inc.
TypeDirect peer
Description

Israel-based clinical-stage biotech developing placenta-derived MSC therapies (PLX cells) for inflammatory and regenerative indications. Comparable as a non-traditional MSC source (placenta vs. uterine cervical) targeting overlapping therapeutic areas with cell-based and cell-derived approaches.

8Regeneus
TypeDirect peer
Description

Australia-based clinical-stage biotech developing adipose-derived stem cell and secretome-based therapies (Progenza, Sygenus) for osteoarthritis and inflammatory pain. Directly comparable as a stem cell-derived secretome platform with similar mechanism and indications.

9Celltex Therapeutics
TypeDirect peer
Description

US-based biotech specializing in autologous and allogeneic mesenchymal stem cell banking and therapy development for degenerative and inflammatory conditions. Peer in the mesenchymal stem cell therapy space with similar regenerative medicine focus.

10Athersys
TypeBroad incumbent
Description

US-based clinical-stage biotech developing MultiStem, a proprietary adult stem cell platform for inflammatory, neurological, and cardiovascular indications. Broader incumbent in regenerative medicine with overlapping platform philosophy and target disease areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gistem Research S.L.

Regenerative Medicine Biotechnologygistemresearch.com

Gistem Research S.L. is a Spanish biotechnology company developing secretome and exosome-based therapies derived from human Uterine Cervical Stem Cells (hUCESC) for ophthalmology, inflammatory bowel disease, oral conditions, oncology, and cerebral palsy applications.

What Gistem Research S.L. does

Gistem Research S.L. is a Spanish biotechnology company founded in 2016 and headquartered in Gijón, Asturias, that develops therapeutic candidates derived from human Uterine Cervical Stem Cells (hUCESC). Its core technology platform centers on the production and application of the cell secretome and exosomes — the bioactive molecules and extracellular vesicles released by these stem cells — rather than the cells themselves. The company advances multiple preclinical programs targeting dry eye disease, inflammatory bowel disease, oral diseases, oncology, and, more recently, cerebral palsy.

Its intellectual property is anchored by patent family PCT/2014/053508, granted in more than 30 jurisdictions including the United States (granted 2025-02-04), Europe (granted 2019-06-17), China, Japan, Mexico, and Australia. Gistem is led scientifically by founders Dr. Francisco Vizoso Piñeiro and Dra. Noemí Eirí­o Díaz, with Dr. Luis Alberto Costa Pérez chairing its Board, and operates with a team of approximately six employees. It maintains a research network with the Jove Hospital Foundation, FICEMU, the University of Santiago de Compostela, the Ministry of Health of Tucumán (Argentina), and the Dale que valen Foundation.

Gistem is pre-clinical and pre-revenue. Its intended business model is to advance its programs through early clinical development and ultimately monetize the platform through out-licensing, co-development partnerships, or future royalty streams; two programs are targeted to enter clinical trials in 2026 and 2027, following positive guidance from the Spanish Medicines Agency on trial design. To date, the only disclosed funding is an IDEPA grant awarded in 2018.

Gistem Research S.L. firmographics

Firmographics
Name
Gistem Research S.L.
Legal name
GISTEM RESEARCH, S.L.
Website
https://gistemresearch.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Gistem Research S.L. is a Spanish biotechnology company developing secretome and exosome-based therapies derived from human Uterine Cervical Stem Cells (hUCESC) for ophthalmology, inflammatory bowel disease, oral conditions, oncology, and cerebral palsy applications.
Ownership category
akta.pro rank

Gistem Research S.L. industry classification

Industry
Product category
Regenerative Medicine Biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell therapies
  • Regenerative medicine
  • Cell secretome research
  • Extracellular vesicles
  • Biotechnology research

Where Gistem Research S.L. is headquartered

Location

Headquarters

HQ city
Gijón
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Gistem Research S.L. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Stem Cell Derivative Products: Development and commercialization of secretome-based therapeutic products for various clinical applications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Revenue expected from future product sales following clinical development.
  2. Technology Licensing: Licensing of proprietary hUCESC technology, cell populations, and production methods to pharmaceutical and biotechnology partners.
  3. Research Collaborations: Collaborative research arrangements with academic institutions and healthcare organizations for specific therapeutic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Gistem Research S.L. product offering

Product offering

Core offering

Gistem Research S.L. develops therapeutic products derived from stem cell derivatives, specifically the secretome and extracellular vesicles (exosomes) from human Uterine Cervical Stem Cells (hUCESC). The company produces these biological materials through reproducible, cost-effective methods and targets multiple clinical indications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Two lead programs are expected to enter clinical trials in 2026 and 2027.

Product overview

Gistem Research S.L. operates as a pioneering biotechnology company focused on developing innovative therapies based on stem cell derivatives. The company's core technology platform centers on hUCESC (human Uterine Cervical Stem Cells) secretome and extracellular vesicles, which are produced in a reproducible and cost-effective manner. The product portfolio includes secretome-based therapeutic products for multiple clinical applications, specifically organized into therapeutic programs targeting Dry Eye Syndrome, Inflammatory Bowel Disease, Oral Diseases, and Oncology. The company's first two programs are expected to enter clinical phase in 2026 and 2027. The therapeutic approach focuses on using stem cell derivatives (secretome and extracellular vesicles) rather than live cells directly, which simplifies regulatory pathways as biological products rather than advanced therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • hUCESC Secretome-based Therapy Secretome-based therapeutic products derived from human Uterine Cervical Stem Cells (hUCESC), containing bioactive molecules offering immunoregulation, healing, and regeneration properties for pharmaceutical partners and healthcare institutions.
  • hUCESC Extracellular Vesicles (Exosomes) Extracellular vesicles derived from human Uterine Cervical Stem Cells (hUCESC), used as therapeutic agents for clinical applications.
  • Dry Eye Syndrome Therapeutic Program Clinical program targeting dry eye syndrome using secretome-based therapy derived from hUCESC, one of the company's first two lead programs.
  • Inflammatory Bowel Disease Therapeutic Program Clinical program targeting inflammatory bowel disease using secretome-based therapy derived from hUCESC.
  • Oral Diseases Therapeutic Program Clinical program targeting oral diseases and dental pulp regeneration using secretome-based therapy derived from hUCESC.
  • Oncology Therapeutic Program Clinical program targeting oncology applications using secretome-based therapy derived from hUCESC, with research showing antitumor effects in breast cancer models.

Quantifiable outcome

  • Improvement in 90% of uveitis cases with current treatment comparison
  • +1 more outcomes

Companies that use Gistem Research S.L.

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Gistem Research S.L. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gistem Research S.L. partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Dale que valen FoundationcoreStrategic or Co-development Partner · 4 March 2026Agreement to establish collaboration framework for research project 'Exploration of the therapeutic effect of intrasanal application of secretome derived from mesenchymal stem cells of the human uterine cervix in cerebral palsy.' Project encompasses complete cycle up to obtaining therapeutic solutions and treatment protocols.
  • Ministry of Health of TucumáncoreStrategic or Co-development Partner · 22 May 2025Framework cooperation agreement between the Ministry of Health of Tucumán (Argentina), GiStem Research S.L., and the Economic Federation for stem cell research. The agreement focuses on secretome-based therapies and includes plans for specific protocols with ethics committee approval for work with selected patients.
  • Economic Federation of Tucumán (FET)coreStrategic or Co-development Partner · 22 May 2025Partnered with Ministry of Health of Tucumán and GiStem Research for stem cell research cooperation. FET facilitated Dr. Luis Costa Pérez's involvement and is financing the project.
  • Jove Hospital FoundationcoreStrategic or Co-development PartnerLong-standing research collaboration with the Jove Hospital Foundation in Gijón, where the research unit is located and where initial stem cell research was conducted.
  • FICEMU (Foundation for Uterine Stem Cell Research)coreStrategic or Co-development PartnerFoundation supporting research with uterine stem cells. Dr. Francisco Vizoso serves as Director of the Scientific Committee. The foundation has financed multiple research projects.
  • University of Santiago de CompostelamajorStrategic or Co-development PartnerAcademic research partner collaborating on various studies including stem cell applications in cancer, ophthalmology, and inflammatory conditions. Located in Galicia, Spain.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Gistem Research S.L. competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: US clinical-stage biotechnology company developing exosome and cell-based therapeutics, notably its lead exosome program CAP-1002 and Deramiocel for Duchenne muscular dystrophy. Directly comparable to Gistem as a stem cell-derived exosome platform targeting inflammatory and regenerative indications.
  • Direct Biologics: US-based biotech developing extracellular vesicle (EV) and exosome-based therapies derived from bone marrow mesenchymal stem cells for inflammatory and regenerative indications including wound healing and orthopedic applications. Closely comparable to Gistem's hUCESC-derived exosome platform in technology and target markets.
  • Kimera Labs: US biotech focused on mesenchymal stem cell-derived exosome products for regenerative and wellness applications. Direct peer in the MSC-exosome therapeutics space with similar therapeutic claims around immunoregulation and tissue regeneration.
  • ExoCoBio: South Korea-based exosome therapeutics developer with MSC-derived exosome products for skin regeneration, atopic dermatitis, and inflammatory conditions. Direct competitor in the cell-derived exosome therapeutics category targeting similar indications.
  • Cynata Therapeutics: Australia-based clinical-stage biotech developing iPSC-derived mesenchymal stem cell therapies (CYP-001, CYP-004) for inflammatory conditions including osteoarthritis and GVHD. Directly comparable MSC-derived therapeutic platform targeting similar regenerative and immunoregulatory indications.
  • Pluri Inc. Israel-based clinical-stage biotech developing placenta-derived MSC therapies (PLX cells) for inflammatory and regenerative indications. Comparable as a non-traditional MSC source (placenta vs. uterine cervical) targeting overlapping therapeutic areas with cell-based and cell-derived approaches.
  • Regeneus: Australia-based clinical-stage biotech developing adipose-derived stem cell and secretome-based therapies (Progenza, Sygenus) for osteoarthritis and inflammatory pain. Directly comparable as a stem cell-derived secretome platform with similar mechanism and indications.
  • Celltex Therapeutics: US-based biotech specializing in autologous and allogeneic mesenchymal stem cell banking and therapy development for degenerative and inflammatory conditions. Peer in the mesenchymal stem cell therapy space with similar regenerative medicine focus.

Broad incumbents

  • Mesoblast: Australia-listed clinical-stage biotech developing mesenchymal stem cell-derived therapies (Remestemcel-L, Ryoncil) for inflammatory and immune-mediated diseases including GVHD and heart failure. Larger, more advanced MSC-therapy incumbent with overlapping technology platform and indication strategy.
  • Athersys: US-based clinical-stage biotech developing MultiStem, a proprietary adult stem cell platform for inflammatory, neurological, and cardiovascular indications. Broader incumbent in regenerative medicine with overlapping platform philosophy and target disease areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Gistem Research S.L. social profiles

Digital presence

Gistem Research S.L. compliance and trust

Trust signal

Compliance2 records

Gistem Research S.L. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gistem Research S.L. leadership team

Management profile

Number of profiles

Profiles9 records

Gistem Research S.L. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gistem Research S.L. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gistem Research S.L.

What does Gistem Research S.L. do?

Gistem Research S.L. develops therapeutic products derived from stem cell derivatives, specifically the secretome and extracellular vesicles (exosomes) from human Uterine Cervical Stem Cells (hUCESC). The company produces these biological materials through reproducible, cost-effective methods and targets multiple clinical indications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Two lead programs are expected to enter clinical trials in 2026 and 2027.

Is Gistem Research S.L. a public or private company?

Gistem Research S.L. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Gistem Research S.L. founded?

Gistem Research S.L. was founded in 2016. It employs 1 to 10 people.

Where is Gistem Research S.L. based?

Gistem Research S.L. is headquartered in Gijón, Spain, in the Europe region.

How does Gistem Research S.L. make money?

Three revenue lines are on record. Stem Cell Derivative Products are the primary driver. The others are technology Licensing and research Collaborations.

Who are Gistem Research S.L.'s main competitors?

Direct peers on record are Capricor Therapeutics, Direct Biologics, Kimera Labs, ExoCoBio, Cynata Therapeutics, Pluri Inc., Regeneus and Celltex Therapeutics. Broad incumbents are Mesoblast and Athersys.

Does Gistem Research S.L. have an API?

No public API is recorded for Gistem Research S.L..

What industry is Gistem Research S.L. in?

Gistem Research S.L.'s product category is Regenerative Medicine Biotechnology. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales